Large phase III randomized clinical trials have proved the efficacy of targeted therapies over conventional cytotoxic chemotherapy for NSCLC patients harboring EGFR mutations [3–6] or ALK fusions [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.